High CCR6/CCR7 expression and Foxp3+ Treg cell number are positively related to the progression of laryngeal squamous cell carcinoma

Oncology Reports

Volumn 30, Issue 3, 2013, Pages 1380-1390

  Chen, Bin ^a,b   Zhang, Duo ^a   Zhou, Jian ^a   Li, Qing ^b   Zhou, Lin ^b   Li, Shi Min ^a   Zhu, Li ^a   Chou, Kuang Yen ^b   Zhou, Liang ^a   Tao, Lei ^a   Lu, Li Ming ^b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CCR6; CCR7; Forkhead box P3; Laryngeal squamous cell carcinoma; Regulatory T cell

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MESSENGER RNA; SECONDARY LYMPHOID TISSUE CHEMOKINE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR IMMUNITY; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYTOKINES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOENZYME TECHNIQUES; LARYNGEAL NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CCR6; RECEPTORS, CCR7; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY;

EID: 84880645005     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2603     Document Type: Article

References (60)

1. Marioni G, Marchese-Ragona R, Cartei G, Marchese F and Staffieri A: Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev 32: 504-515, 2006.
2. Hoffman HT, Porter K, Karnell LH, et al: Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 116: 1-13, 2006.
3. Shah JP, Karnell LH, Hoffman HT, et al: Patterns of care for cancer of the larynx in the United States. Arch Otolaryngol Head Neck Surg 123: 475-483, 1997.
4. Alhamarneh O, Agada F, Madden L, Stafford N and Greenman J: Serum IL10 and circulating CD4(+) CD25(high) regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma. Head Neck 33: 415-423, 2011.
5. Whiteside TL: The tumor microenvironment and its role in promoting tumor growth. Oncogene 27: 5904-5912, 2008.
6. Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307, 2006.
7. Roncarolo MG, Bacchetta R, Bordignon C, Narula S and Levings MK: Type 1 T regulatory cells. Immunol Rev 182: 68-79, 2001.
8. Dieckmann D, Plottner H, Berchtold S, Berger T and Schuler G: Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 193: 1303-1310, 2001.
9. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J and Enk AH: Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 193: 1285-1294, 2001.
10. Levings MK, Sangregorio R and Roncarolo MG: Human cd25(+)cd4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 193: 1295-1302, 2001.
11. Chen Y, Kuchroo VK, Inobe J, Hafler DA and Weiner HL: Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265: 1237-1240, 1994.
12. Sakaguchi S, Yamaguchi T, Nomura T and Ono M: Regulatory T cells and immune tolerance. Cell 133: 775-787, 2008.
13. Sakaguchi S, Miyara M, Costantino CM and Hafler DA: Foxp3+ regulatory T cells in the human immune system. Nat Rev Immunol 10: 490-500, 2010.
14. Xu L, Xu W, Wen Z and Xiong S: In situ prior proliferation of CD4+ CCR6+ regulatory T cells facilitated by TGF-β secreting DCs is crucial for their enrichment and suppression in tumor immunity. PLoS One 6: e20282, 2011.
15. Wei S, Kryczek I and Zou W: Regulatory T-cell compartmentalization and trafficking. Blood 108: 426-431, 2006.
16. Zhu J and Paul WE: CD4 T cells: fates, functions, and faults. Blood 112: 1557-1569, 2008.
17. Mburu YK, Wang J, Wood MA, Walker WH and Ferris RL: CCR7 mediates inflammation-associated tumor progression. Immunol Res 36: 61-72, 2006.
18. Schutyser E, Struyf S and Van Damme J: The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 14: 409-426, 2003.
19. Zlotnik A and Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity 12: 121-127, 2000.
20. Hirahara K, Liu L, Clark RA, Yamanaka K, Fuhlbrigge RC and Kupper TS: The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors. J Immunol 177: 4488-4494, 2006.
21. Wang J, Xi L, Hunt JL, et al: Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res 64: 1861-1866, 2004.
22. Arya M, Patel HR and Williamson M: Chemokines: key players in cancer. Curr Med Res Opin 19: 557-564, 2003.
23. Vinader V and Afarinkia K: A beginner's guide to chemokines. Future Med Chem 4: 845-852, 2012.
24. Tetu B, Popa I, Bairati I, et al: Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Mod Pathol 21: 1002-1010, 2008.
25. Waugh DJ and Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res 14: 6735-6741, 2008.
26. Müller A, Homey B, Soto H, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56, 2001.
27. Forster R, Davalos-Misslitz AC and Rot A: CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 8: 362-371, 2008.
28. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P and Bonecchi R: The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev 21: 27-39, 2010.
29. Ghadjar P, Coupland SE, Na IK, et al: Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol 24: 1910-1916, 2006.
30. Wittekind C, Compton CC, Greene FL and Sobin LH: TNM residual tumor classification revisited. Cancer 94: 2511-2516, 2002.
31. Pavelic ZP, Pavelic K, Carter CP and Pavelic L: Heterogeneity of c-myc expression in histologically similar infiltrating ductal carcinomas of the breast. J Cancer Res Clin Oncol 118: 16-22, 1992.
32. Tao L, Zhou L, Zheng L and Yao M: Elemene displays anti-cancer ability on laryngeal cancer cells in vitro and in vivo. Cancer Chemother Pharmacol 58: 24-34, 2006.
33. Lefebvre JL and Ang KK: Larynx preservation clinical trial design: key issues and recommendations - a consensus panel summary. Head Neck 31: 429-441, 2009.
34. Chen AY, Schrag N, Hao Y, et al: Changes in treatment of advanced laryngeal cancer 1985-2001. Otolaryngol Head Neck Surg 135: 831-837, 2006.
35. Holsinger FC and Weber RS: Swing of the surgical pendulum: a return to surgery for treatment of head and neck cancer in the 21st century? Int J Radiat Oncol Biol Phys 69 (Suppl 2): S129-S131, 2007
36. Laccourreye O, Brasnu D, Bassot V, Menard M, Khayat D and Laccourreye H: Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: five-year results. J Clin Oncol 14: 2331-2336, 1996.
37. Lefebvre JL, Rolland F, Tesselaar M, et al: Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 101: 142-152, 2009.
38. Stenson KM, Maccracken E, Kunnavakkam R, et al: Chemoradiation for patients with large-volume laryngeal cancers. Head Neck 34: 1162-1167, 2012.
39. Beider K, Abraham M, Begin M, et al: Interaction between CXCR4 and CCL20 pathways regulates tumor growth. PLoS One 4: e5125, 2009.
40. Bonnotte B, Crittenden M, Larmonier N, Gough M and Vile RG: MIP-3alpha transfection into a rodent tumor cell line increases intratumoral dendritic cell infiltration but enhances (facilitates) tumor growth and decreases immunogenicity. J Immunol 173: 4929-4935, 2004.
41. Cabioglu N, Yazici MS, Arun B, et al: CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res 11: 5686-5693, 2005.
42. Shang ZJ, Liu K and Shao Z: Expression of chemokine receptor CCR7 is associated with cervical lymph node metastasis of oral squamous cell carcinoma. Oral Oncol 45: 480-485, 2009.
43. Takanami I: Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer 105: 186-189, 2003.
44. Chen KJ, Lin SZ, Zhou L, et al: Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One 6: e24671, 2011.
45. Annunziato F, Cosmi L, Liotta F, et al: Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. J Exp Med 196: 379-387, 2002.
46. Iellem A, Mariani M, Lang R, et al: Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 194: 847-853, 2001.
47. Xu L, Xu W, Qiu S and Xiong S: Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer. Clin Immunol 135: 466-475, 2010.
48. Kosmaczewska A, Ciszak L, Potoczek S and Frydecka I: The significance of Treg cells in defective tumor immunity. Arch Immunol Ther Exp (Warsz) 56: 181-191, 2008.
49. Mao C, Wang S, Jiang Q, et al: Increased CD4+CD25+Foxp3+ regulatory T cells in cancer patients from conversion of CD4+CD25- T cells through tumor-derived factors. Onkologie 31: 243-248, 2008.
50. Pakravan N, Hassan AT and Hassan ZM: Naturally occurring self-reactive CD4+CD25+ regulatory T cells: universal immune code. Cell Mol Immunol 4: 197-201, 2007.
51. + T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13: 4345-4354, 2007.
52. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345-352, 2005.
53. Ebert LM, Tan BS, Browning J, et al: The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res 68: 3001-3009, 2008.
54. Karanikas V, Speletas M, Zamanakou M, et al: Foxp3 expression in human cancer cells. J Transl Med 6: 19, 2008.
55. Ladoire S, Arnould L, Mignot G, et al: Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 125: 65-72, 2011.
56. O'Hayre M, Salanga CL, Handel TM and Allen SJ: Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J 409: 635-649, 2008.
57. Ito S, Ozawa S, Ikoma T, Yajima N, Kiyono T and Hata R: Expression of a chemokine BRAK/CXCL14 in oral floor carcinoma cells reduces the settlement rate of the cells and suppresses their proliferation in vivo. Biomed Res 31: 199-206, 2010.
58. Silva TA, Ribeiro FL, Oliveira-Neto HH, et al: Dual role of CCL3/CCR1 in oral squamous cell carcinoma: Implications in tumor metastasis and local host defense. Oncol Rep 18: 1107-1113, 2007.
59. Sakaguchi S, Sakaguchi N, Asano M, Itoh M and Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155: 1151-1164, 1995.
60. DiPersio JF, Micallef IN, Stiff PJ, et al: Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 27: 4767-4773, 2009.